- Home
- IMNM
IMNM
Immunome Inc.
as 10-17-2024 4:00pm EST
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 747.7M | IPO Year: | 2020 |
| Target Price: | $28.75 | AVG Volume (30 days): | 761.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.93 - $30.96 | Next Earning Date: | 11-07-2024 |
| Revenue: | $10,784,000 | Revenue Growth: | 62.73% |
| Revenue Growth (this year): | -38.89% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunome Inc. (IMNM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rosett Max | IMNM | Chief Financial Officer | Sep 19 '24 | Sell | $16.01 | 14,380 | $230,223.80 | 47,476 | |
| BIENAIME JEAN JACQUES | IMNM | Director | Aug 15 '24 | Buy | $13.94 | 7,000 | $97,608.00 | 16,615 | |
| Higgins Jack | IMNM | Chief Scientific Officer | Aug 15 '24 | Sell | $13.93 | 3,524 | $49,071.70 | 16,000 |
Latest Immunome Inc. News
IMNM Breaking Stock News: Dive into IMNM Ticker-Specific Updates for Smart Investing
Business Wire
10 days ago
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
Business Wire
10 days ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
a month ago
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
Business Wire
2 months ago
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Investor's Business Daily
2 months ago
Immunome Stock Sees RS Rating Jump To 91
Simply Wall St.
2 months ago
Immunome Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Zacks
2 months ago
Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
MT Newswires
2 months ago
Immunome Q2 Net Loss Widens, Revenue Drops
Compare IMNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNM Immunome Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.